Juan J. Sevilla-Rodriguez

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications

Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasms.

Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasms.

Journal: Blood advances
Published: April 08, 2026

Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.

Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.

Journal: Blood cancer journal
Published: December 04, 2025

Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia.

Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia.

Journal: Blood cancer discovery
Published: July 17, 2025

Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia.

Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia.

Journal: Blood advances
Published: June 04, 2025

Autophagy and oxidative stress in solid tumors: Mechanisms and therapeutic opportunities.

Autophagy and oxidative stress in solid tumors: Mechanisms and therapeutic opportunities.

Journal: Critical reviews in oncology/hematology
Published: May 12, 2025

Unveiling relative lymphopenia and elevated monocyte-to-lymphocyte count as novel independent adverse prognostic factors in chronic myelomonocytic leukemia (CMML)-Proposal of the objective prognostic index for CMML (OPIC).

Unveiling relative lymphopenia and elevated monocyte-to-lymphocyte count as novel independent adverse prognostic factors in chronic myelomonocytic leukemia (CMML)-Proposal of the objective prognostic index for CMML (OPIC).

Journal: HemaSphere
Published: May 06, 2025

Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion.

Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion.

Journal: Leukemia research
Published: October 01, 2024

Natural killer cells' functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes.

Natural killer cells' functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes.

Journal: Nature communications
Published: September 19, 2024

BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML.

BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML.

Journal: Science translational medicine
Published: September 11, 2024

Inflammation in myelodysplastic syndrome pathogenesis.

Inflammation in myelodysplastic syndrome pathogenesis.

Journal: Seminars in hematology
Published: September 07, 2024

A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.

A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.

Journal: Leukemia research
Published: August 06, 2024

The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial.

The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial.

Journal: Nature communications
Published: July 15, 2024
Showing 1-12 of 63

Last Updated: 09/26/2026